Other disease areas
Our medicines and vaccines have an important impact for patients.
Our dedication in other disease areas
We are selectively active in the fields of inflammation and autoimmunity, infection and vaccines, and neuroscience. We pursue an opportunity-oriented approach and often work in partnerships.
Inflammation and Autoimmunity
We seek to develop novel treatments for a breadth of inflammatory and autoimmune diseases.
Our research efforts are focused on gaining a better understanding of the common biology and shared molecular pathways among inflammatory and autoimmune diseases, as well as the fundamental drivers and mechanisms of disease.
This approach enables us to identify and select drug targets that have the potential to effectively treat not just one, but multiple inflammatory and autoimmune diseases.
Infection and Vaccines
We are committed to developing and implementing scientific advancement in infection and vaccines.
We work to protect patients against the burden of influenza, respiratory syncytial virus (RSV) and bacterial infections, particularly those resistant to current antibiotics. Antibiotic resistance in particular is developing into a global medical challenge.
Through working with the wider infection community, we want to contribute to overcoming the global burden of disease.
Neuroscience
We aim to advance the science of neurodegenerative diseases to help patients around the world.
A significant unmet medical need remains in the areas of cognitive disorders, chronic pain and other central nervous system disorders.
With our rich heritage and a research and development focus on specific aspects of neurodegenerative diseases, analgesia and psychiatry, we continue to push the boundaries of science in collaboration with other innovative partners across industry and academia.
Join AstraZeneca
and help us deliver life-changing medicines.
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.
CH-2305; 03/2020